MANUAL ARTICLE REVIEW IS REQUIRED FOR THIS ARTICLE

Manual article review is required for this article

Genomic sequencing analysis of 733 HER2-amplified Key and metastatic breast tumours unveiled major enrichment of mutations that activate RAS–MAPK signalling in Superior tumours taken care of with prior anti-HER2 therapies121. These mutations, like NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib.MRI devices use a m